Issue 82, 2017

Platinum(iv) oxaliplatin–peptide conjugates targeting memHsp70+ phenotype in colorectal cancer cells

Abstract

Novel Pt(IV) tumour penetrating peptide (TPP) conjugates are reported. They are the first example of metallodrugs to target a membrane bound heat shock protein 70 positive (memHSP70+) phenotype in cancer cells. The conjugates exhibit superior cytotoxicity as compared to oxaliplatin alone in Pt resistant colorectal cancer cells with relatively high memHSP70+ expression. Substitution of TPP in Pt(IV) peptide conjugates with scrambled peptide (ScP) essentially abolishes the observed cytotoxicity.

Graphical abstract: Platinum(iv) oxaliplatin–peptide conjugates targeting memHsp70+ phenotype in colorectal cancer cells

Supplementary files

Article information

Article type
Communication
Submitted
19 Jun 2017
Accepted
25 Sep 2017
First published
25 Sep 2017

Chem. Commun., 2017,53, 11318-11321

Platinum(IV) oxaliplatin–peptide conjugates targeting memHsp70+ phenotype in colorectal cancer cells

A. M. McKeon, J. Noonan, M. Devocelle, B. M. Murphy and D. M. Griffith, Chem. Commun., 2017, 53, 11318 DOI: 10.1039/C7CC04764A

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements